TG Therapeutics Raises 2026 Revenue Guidance to About $1 Billion
TG Therapeutics reported third-quarter 2026 revenue of $259.9 million and net income of $55.5 million. It raised its 2026 global revenue target to approximately $1 billion and its BRIUMVI U.S. net product revenue target to $915 million–$920 million.
TG Therapeutics reported third-quarter 2026 revenue of $259.9 million and net income of $55.5 million. The company raised its 2026 total global revenue target to approximately $1 billion and its BRIUMVI U.S. net product revenue target to $915 million—$920 million. Cash, cash equivalents and investm…